Antman E M
Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Am J Cardiol. 1996 Aug 29;78(4A):67-72. doi: 10.1016/s0002-9149(96)00455-9.
Management of atrial fibrillation is a common and complex clinical problem. Two major treatment strategies have emerged: suppression of recurrences versus control of ventricular rate and anticoagulation to reduce the risk of stroke. Maintaining sinus rhythm offers the hemodynamic benefits of improving ventricular performance and exercise capacity but may expose the patient to the risk of proarrhythmia/sudden death and drug-related morbidity. Controlling ventricular rate helps decrease symptomatic palpitations and improve exercise capacity but necessitates long-term anticoagulation (which may also be needed despite the use of antiarrhythmics to suppress recurrences of atrial fibrillation) with some risk of bleeding. Randomized trials are now needed to define the relative benefits of these 2 treatment strategies. Such trials should be designed to provide information on the impact of the 2 approaches on symptoms, exercise capacity, quality of life, and mortality rate in patients with atrial fibrillation.
心房颤动的管理是一个常见且复杂的临床问题。已出现两种主要治疗策略:抑制复发与控制心室率以及抗凝以降低中风风险。维持窦性心律可带来改善心室功能和运动能力的血流动力学益处,但可能使患者面临心律失常/猝死和药物相关发病率的风险。控制心室率有助于减少症状性心悸并提高运动能力,但需要长期抗凝(即使使用抗心律失常药物抑制心房颤动复发也可能需要抗凝),存在一定出血风险。现在需要进行随机试验来确定这两种治疗策略的相对益处。此类试验应旨在提供关于这两种方法对心房颤动患者的症状、运动能力、生活质量和死亡率影响的信息。